|

Add a bookmark to get started

Bookmarks info

Brian Hamano

Socio
Los AngelesPalo Alto
About

Brian Hamano represents clients in a broad range of U.S. and international tax matters and has expertise in structuring and negotiating mergers and acquisitions, divestitures, joint ventures, recapitalizations and financing transactions. Brian regularly advises founders and start-ups on the business and tax aspects of company exit strategies and the "qualified small business stock" exemption under Section 1202 of the Internal Revenue Code.

Brian was recognized in The Legal 500 for both US Taxes: Non-Contentious (2024) and International Tax (2024), has been a speaker at numerous tax conferences (including the USC Gould School of Law Tax Institute and for Tax Executives Institute) and has written for Tax Notes.

Areas of FocusImpuestosTransactional TaxCapital privadoFusiones y adquisicionesCiencias de la vida
Bar admissionsCaliforniaNueva York

Representative Matters

  • Alimera Sciences (Nasdaq: ALIM) in its proposed sale to ANI Pharmaceuticals for approximately $430 million
  • Super Micro Computer, Inc. (Nasdaq: SMCI) in its $1.75 billion convertible notes offering
  • DocuSmart (dba Lexion) in its sale to Docusign (Nasdaq: DOCU) for $165 million
  • insightsoftware in its acquisition of LeaseAccelerator (undisclosed)
Education
  • Executive LL.M., New York University

  • J.D., University of Michigan
    cum laude

  • B.A., University of California – Los Angeles
    magna cum laude

AWARDS AND RECOGNITION

The Legal 500 United States

  • Recognized, US Taxes: Non-Contentious (2024)
  • Recognized, International Tax (2024)
Additional Awards
  • Recognized, "Ones to Watch in America in Tax Law," Best Lawyers® (2021- 2023)

Prior Experience

Prior to joining DLA Piper, Brian practiced in the New York offices of two AmLaw 50 international law firms.

Memberships and Affiliations

  • Member, American Bar Association, Tax Section

My latest insights

News

DLA Piper advises N-able, Inc. in its acquisition of Adlumin, Inc.

25 de noviembre de 2024 .2 minute read

News

DLA Piper advises Alimera Sciences in acquisition by ANI Pharmaceuticals

27 de junio de 2024 .2 minute read

News

DLA Piper advises Supermicro in its issuance of US$1.725 billion in 0.0% convertible notes

27 de febrero de 2024 .2 minute read

View All

Connect

Phone

+1 310 595 3095
(Work, Los Angeles)
+1 650 833 2000
(Work , Palo Alto)
CallvCardLinkedInPrint
Avisos legalesPolítica de cookiesPolítica de privacidad Mapa del sitio

DLA Piper es una firma de abogados global que opera a través de varias entidades legales distintas e independientes. Para obtener más información sobre esas entidades y sobre la estructura de DLA Piper, consulte la página Avisos legales de este sitio web. Todos los derechos reservados. Publicidad de abogados. © 2023 DLA Piper